Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine

Satish Sanku Chander Rao, P. A. Cann, C. D. Holdsworth

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

We assessed the tolerance and safety of two new preparations designed to release 5-aminosalicylic acid in the colon in patients with ulcerative colitis who were intolerant of sulphasalazine. Twenty-eight of 37 patients (76% given mesalazine and 18 of 21 patients (86% given olsalazine tolerated the new preparations with no adverse effects. No haematologic or biochemical abnormalities were detected. Adverse reactions to the new preparations were usually but not always similar to those they had previously encountered with sulphasalazine, but a few patients experienced rash and diarrhoea. In some patients intolerant of one of the new preparations, their tolerance of the other was assessed. Three patients intolerant of mesalazine tolerated olsalazine. Similarly, three other patients intolerant of olsalazine tolerated mesalazine. We conclude that not all adverse effects of sulphasalazine are due to the sulphapyridine part of the molecule. Some are due to the released 5-aminosalicylic acid and some to the parent compound. Both drugs are likely to prove useful in the management of patients intolerant of sulphasalazine.

Original languageEnglish (US)
Pages (from-to)332-336
Number of pages5
JournalScandinavian Journal of Gastroenterology
Volume22
Issue number3
DOIs
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Mesalamine
Sulfasalazine
Sulfapyridine
olsalazine
Exanthema
Ulcerative Colitis
Diarrhea
Colon
Safety

Keywords

  • Mesalazine
  • Olsalazine
  • Sulphasalazine intolerance
  • Tolerance
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. / Rao, Satish Sanku Chander; Cann, P. A.; Holdsworth, C. D.

In: Scandinavian Journal of Gastroenterology, Vol. 22, No. 3, 01.01.1987, p. 332-336.

Research output: Contribution to journalArticle

@article{d2647802c2294fb1809b5d9a7127356c,
title = "Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine",
abstract = "We assessed the tolerance and safety of two new preparations designed to release 5-aminosalicylic acid in the colon in patients with ulcerative colitis who were intolerant of sulphasalazine. Twenty-eight of 37 patients (76{\%} given mesalazine and 18 of 21 patients (86{\%} given olsalazine tolerated the new preparations with no adverse effects. No haematologic or biochemical abnormalities were detected. Adverse reactions to the new preparations were usually but not always similar to those they had previously encountered with sulphasalazine, but a few patients experienced rash and diarrhoea. In some patients intolerant of one of the new preparations, their tolerance of the other was assessed. Three patients intolerant of mesalazine tolerated olsalazine. Similarly, three other patients intolerant of olsalazine tolerated mesalazine. We conclude that not all adverse effects of sulphasalazine are due to the sulphapyridine part of the molecule. Some are due to the released 5-aminosalicylic acid and some to the parent compound. Both drugs are likely to prove useful in the management of patients intolerant of sulphasalazine.",
keywords = "Mesalazine, Olsalazine, Sulphasalazine intolerance, Tolerance, Ulcerative colitis",
author = "Rao, {Satish Sanku Chander} and Cann, {P. A.} and Holdsworth, {C. D.}",
year = "1987",
month = "1",
day = "1",
doi = "10.3109/00365528709078600",
language = "English (US)",
volume = "22",
pages = "332--336",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine

AU - Rao, Satish Sanku Chander

AU - Cann, P. A.

AU - Holdsworth, C. D.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - We assessed the tolerance and safety of two new preparations designed to release 5-aminosalicylic acid in the colon in patients with ulcerative colitis who were intolerant of sulphasalazine. Twenty-eight of 37 patients (76% given mesalazine and 18 of 21 patients (86% given olsalazine tolerated the new preparations with no adverse effects. No haematologic or biochemical abnormalities were detected. Adverse reactions to the new preparations were usually but not always similar to those they had previously encountered with sulphasalazine, but a few patients experienced rash and diarrhoea. In some patients intolerant of one of the new preparations, their tolerance of the other was assessed. Three patients intolerant of mesalazine tolerated olsalazine. Similarly, three other patients intolerant of olsalazine tolerated mesalazine. We conclude that not all adverse effects of sulphasalazine are due to the sulphapyridine part of the molecule. Some are due to the released 5-aminosalicylic acid and some to the parent compound. Both drugs are likely to prove useful in the management of patients intolerant of sulphasalazine.

AB - We assessed the tolerance and safety of two new preparations designed to release 5-aminosalicylic acid in the colon in patients with ulcerative colitis who were intolerant of sulphasalazine. Twenty-eight of 37 patients (76% given mesalazine and 18 of 21 patients (86% given olsalazine tolerated the new preparations with no adverse effects. No haematologic or biochemical abnormalities were detected. Adverse reactions to the new preparations were usually but not always similar to those they had previously encountered with sulphasalazine, but a few patients experienced rash and diarrhoea. In some patients intolerant of one of the new preparations, their tolerance of the other was assessed. Three patients intolerant of mesalazine tolerated olsalazine. Similarly, three other patients intolerant of olsalazine tolerated mesalazine. We conclude that not all adverse effects of sulphasalazine are due to the sulphapyridine part of the molecule. Some are due to the released 5-aminosalicylic acid and some to the parent compound. Both drugs are likely to prove useful in the management of patients intolerant of sulphasalazine.

KW - Mesalazine

KW - Olsalazine

KW - Sulphasalazine intolerance

KW - Tolerance

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=0023136492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023136492&partnerID=8YFLogxK

U2 - 10.3109/00365528709078600

DO - 10.3109/00365528709078600

M3 - Article

C2 - 2884724

AN - SCOPUS:0023136492

VL - 22

SP - 332

EP - 336

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 3

ER -